查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1808682

多重抗药性结核病 (MDR-TB) 治疗市场（按药物类别、给药途径、治疗类型、治疗方案长度、最终用户和分销管道划分）- 全球预测，2025-2030 年

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Route Of Administration, Treatment Type, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

多重抗药性结核病 (MDR-TB) 治疗市场预计到 2024 年将达到 3.7053 亿美元，到 2025 年将达到 4.11 亿美元，到 2030 年将达到 7.0058 亿美元，复合年增长率为 11.19%。

主要市场统计数据
基准年2024年 3.7053亿美元
预计2025年 4.11亿美元
预测年份 2030 7.058亿美元
复合年增长率（%） 11.19%

了解在快速发展的全球卫生背景下治疗多重抗药性结核病（MDR-TB）的紧​​迫性和多方面挑战

结核病对多种第一线药物的抗药性构成了威胁，需要紧急采取行动。耐多药率的上升使临床管理更加复杂，延长了治疗时间，并增加了医疗系统的负担。对异烟肼和利福平等关键药物产生抗药性的菌株的出现凸显了现有治疗通讯协定的脆弱性，也凸显了开发新方法的必要性。因此，公共卫生、临床和药物研发的相关人员正在重新评估控制和治疗这种持续性感染疾病的策略。

描绘治疗领域的重大转变，将重新定义全球多重抗药性结核病 (MDR-TB) 治疗途径

近年来，新型化合物的引入和现有抗生素的再利用，导致了多重抗药性结核病 (MDR-TB) 治疗模式转移。贝达喹啉和Linezolid等药物因其对抗药性菌株的疗效而备受关注，而新型候选药物则有望提供更短、更耐受的治疗方案。同时，协同联合治疗的研究正在加速从长期、毒性大的治疗到标靶治疗的转变，从而提高患者的依从性和治疗效果。

评估 2025 年美国关税对多重抗药性结核病 (MDR-TB) 治疗供应链和全球成本结构的累积影响

美国将于2025年实施关税，这给耐多药结核病（MDR-TB）治疗药物供应链带来了重大挑战。关键原料药成分原料成本的上涨，迫使药厂重新评估筹资策略。入境口岸的延误和行政负担的增加，进一步加剧了物流压力，并延长了运往高负担地区的关键药物的前置作业时间。这些中断可能会损害治疗的连续性，并加剧医疗机构的财务压力。

透过详细的細項分析揭示了耐多药结核病治疗的多样化治疗方式和分布动态的关键见解

按药物类别细分市场，可以清楚揭示需求模式和治疗偏好。贝达喹啉凭藉其强大的临床表现，继续成为抗药性病例的基石药物，而氯法齐明则因其在组合方案中的协同作用而日益受到青睐。异烟肼因其历史地位和成本效益而仍然至关重要，此外，Linezolid在复杂病例中的应用日益广泛，利福平在骨干治疗中的策略性应用也为其提供了补充。每种药物独特的安全性和抗药性抑制能力决定了其在各种治疗方案中的地位。

重点介绍影响全球主要市场多重抗药性结核病 (MDR-TB) 治疗覆盖率和可及性的关键区域动态

在美洲，先进的医疗基础设施和有针对性的公共卫生倡议相结合，正在加速将新型抗生素纳入治疗指南。在强大的药物安全检测体系的支持下，北美在贝达喹啉和再利用药物的快速核准方面处于领先地位。同时，拉丁美洲国家正在加强诊断网络，并协商分级定价，以改善偏远社区的药物可近性。政府和非政府合作的重点是保障供应和能力建设，以应对高发地区。

确定推动多重抗药性结核病 (MDR-TB) 治疗和医疗保健成果的主要企业的策略和创新

主要企业正在采取多管齐下的策略来应对多重抗药性结核病 (MDR-TB) 治疗的复杂性。贝达喹啉的开发和全球推广就是一个显着的例子，它展示了标靶药物研发改变临床疗效的潜力。联合授权合约使学名药药製造商能够以更低的成本生产贝达喹啉，从而扩大了疾病负担最重地区的可及性。这种方法表明，原厂药和本地生产商之间的战略伙伴关係关係如何在不影响品质的情况下优化价格承受能力。

行动建议使产业领导者能够增强多重抗药性结核病药物的可及性、优化供应链并加速创新

相关人员应优先考虑与本地生产商合作，以减少对国际进口的依赖，并防范关税造成的成本波动。与区域製造商建立合资企业和签订授权协议可以增强供应链的韧性，并促进技术转移。同时，透过引入多家原料药)供应商来实现采购管道的多元化，可以降低单一来源中断带来的风险，同时支援具有竞争力的定价和关键化合物的持续供应。

描述支持对多重抗药性结核病（MDR-TB）治疗进行全面监测的严格调查方法和分析框架

本研究综合了大量的二手资料，旨在对目前的治疗现状和抗药性模式建立基础理解。本研究系统性地回顾了同行评审的临床文献、全球卫生组织治疗指南和临床试验註册库，以了解主要抗生素的疗效概况。监管通知和政策文件提供了有关进口关税、定价策略和市场准入的见解。本研究整合了公共卫生资料库的讯息，将当地治疗方案与患者人口统计联繫起来。

观点强调，需要齐心协力、持续创新，以应对耐多药结核病药物的全球威胁

分析证实，应对多重抗药性结核病 (MDR-TB) 需要製定协调一致的策略，在治疗方法创新与加强卫生系统之间取得平衡。药物研发和诊断技术的突破性进展为改善患者预后创造了前所未有的机会，但这些进展必须得到有韧性的供应网络和支持性政策框架的支持。确保公平获得新型疗法，取决于相关人员应对监管复杂性、优化采购机制以及在不同医疗机构之间调动资源的能力。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 口服贝达喹啉和德拉马尼疗法作为注射剂的替代品的应用日益增多
  • 加速核准用于治疗多重抗药性结核病（MDR-TB）的新型化合物的监管途径
  • 整合快速分子诊断与数位依从技术，实现个人化结核病治疗
  • 固定剂量联合治疗的出现，缩短了多重抗药性结核病（MDR-TB）患者的治疗时间
  • 价格谈判倡议和捐助方资助计画旨在改善低收入国家获得贝达喹啉的途径
  • 硝基咪唑类药物与普利托马尼联合治疗的临床试验数据将有助于更新世卫组织治疗指南
  • 开发宿主导向疗法和抗生素疗法，以减少肺损伤并改善预后
  • 利用人工智慧模型预测结核病抗药性并优化个人化耐多药结核病治疗方案
  • 扩大照护现场治疗药物监测，实现多重抗药性结核病 (MDR-TB) 治疗中的个人化药物剂量
  • 开发一种吸入式抗菌製剂，用于靶向肺部输送，以减少耐多药结核病（MDR-TB）难治性病例的全身毒性

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 多重抗药性结核病（MDR-TB）治疗市场（依药物类别）

  • 贝达喹啉
  • 氯法齐明
  • 异烟肼
  • Linezolid
  • 利福平

9. 多重抗药性结核病（MDR-TB）治疗市场（依给药途径）

  • 注射
  • 口服

10. 多重抗药性结核病（MDR-TB）治疗市场（依治疗类型）

  • 药物治疗
  • 非药物治疗

11. 多重抗药性结核病（MDR-TB）治疗市场（依治疗方案长度）

  • 长期规划
  • 短期规划

12. 多重抗药性结核病（MDR-TB）治疗市场（依最终用户）

  • 医院
  • 专科诊所

13. 多重抗药性结核病（MDR-TB）治疗市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

14.美洲多重抗药性结核病（MDR-TB）治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 欧洲、中东和非洲多重抗药性结核病（MDR-TB）治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

16. 亚太耐多药结核病（MDR-TB）治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • GlaxoSmithKline plc
    • Johnson & Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd
    • Abcam Limited
    • Eli Lilly and Company
    • Lupin Limited
    • Macleods Pharmaceuticals Ltd.
    • Merck & Co., Inc.
    • Mylan NV
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Sanofi SA
    • WebMD LLC
    • Viatris Inc.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-7A22CB0E5A7D

The Multidrug-resistant Tuberculosis Therapeutics Market was valued at USD 370.53 million in 2024 and is projected to grow to USD 411.00 million in 2025, with a CAGR of 11.19%, reaching USD 700.58 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 370.53 million
Estimated Year [2025] USD 411.00 million
Forecast Year [2030] USD 700.58 million
CAGR (%) 11.19%

Unveiling the Urgency and Multifaceted Challenges of Multidrug-Resistant Tuberculosis Therapeutics in a Rapidly Evolving Global Health Context

Tuberculosis that resists multiple first-line drugs presents a growing threat that demands immediate attention. Rising rates of multidrug resistance have complicated clinical management, extending treatment durations and amplifying the burden on healthcare systems. The emergence of strains resistant to cornerstone medications such as isoniazid and rifampin has unveiled vulnerabilities in existing therapeutic protocols and underscored the necessity for novel approaches. As a result, stakeholders across public health, clinical practice, and pharmaceutical development are reevaluating strategies to contain and treat this persistent disease.

Global health authorities emphasize that delays in diagnosis and gaps in treatment adherence contribute significantly to resistance patterns. In regions where healthcare infrastructure is already strained, ensuring consistent drug supply chains and monitoring patient outcomes becomes an uphill task. Moreover, drug-resistant infections often require combinations of second- and third-line agents, which can introduce complex side-effect profiles and elevated costs. These factors collectively increase the urgency for a coordinated, data-driven response that tailors interventions to emerging resistance trends.

This executive summary provides a comprehensive overview of the current landscape for multidrug-resistant tuberculosis therapeutics. It examines recent transformative shifts, the impact of United States tariffs in 2025 on supply chains, critical segmentation and regional insights, influential company strategies, and actionable recommendations for industry leaders. Detailed methodology and conclusive perspectives pave the way for informed decision-making and sustained innovation in the battle against multidrug-resistant tuberculosis.

Charting Major Transformative Shifts in the Therapeutic Landscape That Redefine Treatment Pathways for Multidrug-Resistant Tuberculosis Worldwide

Recent years have witnessed a paradigm shift in the treatment of multidrug-resistant tuberculosis, driven by the introduction of novel compounds and the repurposing of existing antibiotics. Agents such as bedaquiline and linezolid have gained prominence for their efficacy against resistant strains, while emerging candidates offer the promise of shorter, more tolerable regimens. Concurrently, research into synergistic combinations has accelerated the move away from prolonged, highly toxic treatment courses toward targeted therapies that improve patient adherence and outcomes.

The integration of advanced diagnostics and digital health tools has further reshaped therapeutic decision-making. Rapid molecular assays enable clinicians to identify resistance patterns within days, facilitating personalized treatment strategies. Mobile health platforms and electronic adherence monitoring have enhanced patient engagement, reducing default rates and enabling timely interventions. These innovations collectively foster a more agile response to resistance-driven challenges, aligning clinical practice with the expanding arsenal of pharmacological options.

As these transformative shifts converge, pharmaceutical developers, clinicians, and public health agencies must adapt to evolving treatment protocols. Stakeholders are challenged to integrate multi-drug regimens, invest in training for new diagnostic workflows, and collaborate on patient support mechanisms. This section underscores the critical need for cross-sector coordination to harness recent advances, ensuring that therapeutic innovations translate into tangible improvements in global tuberculosis control efforts.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Multidrug-Resistant Tuberculosis Therapeutics Supply Chains and Cost Structures Globally

The implementation of United States tariffs in 2025 has introduced significant challenges across the supply chains of multidrug-resistant tuberculosis therapeutics. Raw material costs for essential active pharmaceutical ingredients have surged, prompting pharmaceutical manufacturers to reevaluate sourcing strategies. Delays at ports of entry and increased administrative burdens have further strained logistics, extending lead times for critical medications destined for high-burden regions. These disruptions risk undermining treatment continuity and exacerbate the financial pressures on healthcare providers.

Beyond the immediate cost increases, tariffs have had downstream effects on pricing frameworks in both domestic and international markets. Wholesalers and distributors face compressed margins, compelling them to pass higher costs onto end users, including governments and non-profit organizations. In low- and middle-income countries reliant on imported medications, the cumulative financial impact may translate into reduced procurement volumes or compromises in regimen selection. Consequently, some national tuberculosis control programs are exploring alternative suppliers or engaging in bulk purchasing agreements to mitigate the tariff-driven cost escalation.

In response to these challenges, stakeholders are pursuing strategic initiatives to safeguard access and affordability. Investments in local production facilities aim to decrease dependence on imported APIs, while partnerships between public and private sectors focus on supply chain resilience. Policy dialogues with trade authorities seek exemptions or reductions for essential health commodities. Through these collaborative efforts, it is possible to navigate the complexities introduced by tariffs and sustain progress in treating multidrug-resistant tuberculosis on a global scale.

Revealing Key Insights from In-Depth Segmentation Analyses Illuminating the Diverse Treatment Modalities and Distribution Dynamics of MDR Tuberculosis Therapies

Segmenting the market by drug class reveals distinct demand patterns and therapeutic preferences. Bedaquiline continues to lead as a cornerstone in resistant cases due to its strong clinical profile, while clofazimine gains traction for its synergistic effect in combination regimens. Isoniazid remains integral for its historical role and cost efficiency, complemented by the increased adoption of linezolid for complex cases and the strategic use of rifampin in backbone therapies. Each agent's unique safety profile and resistance suppression capabilities shape its positioning in varied treatment protocols.

Exploring segmentation by route of administration highlights the growing dominance of oral formulations, which offer improved patient compliance and reduced healthcare facility burdens. Injectable options, although critical for severe or rapidly progressive infections, demand greater healthcare resources and carry higher administration costs. When viewed through the lens of treatment type, medication-based therapies maintain primacy, while emerging non-medication interventions, such as adjunctive immunotherapies and personalized supportive care, underscore a broader shift toward holistic patient management. Treatment regimen duration segmentation further distinguishes between long-course protocols that ensure comprehensive eradication and shorter regimens designed to balance efficacy with tolerability and adherence.

End users in hospitals and specialty clinics play pivotal roles in delivering MDR tuberculosis care, with hospital settings offering comprehensive inpatient support and specialty clinics facilitating outpatient management and follow-up. Distribution dynamics span hospital pharmacies that serve inpatient needs, online pharmacies that expand geographic reach, and retail pharmacies that increase community accessibility. Understanding these end-user and distribution channel insights is essential for tailoring manufacturing strategies, optimizing inventory management, and enhancing outreach to diverse patient populations.

Highlighting Critical Regional Dynamics Shaping the Adoption and Accessibility of Multidrug-Resistant Tuberculosis Treatments across Major Global Markets

In the Americas, a blend of advanced healthcare infrastructure and targeted public health initiatives has accelerated the integration of novel antimicrobials into treatment guidelines. North America leads with rapid regulatory approvals for bedaquiline and repurposed agents, supported by robust pharmacovigilance systems. Meanwhile, Latin American countries are strengthening diagnostic networks and negotiating tiered pricing to improve access in remote communities. Collaborative efforts between governments and non-governmental organizations focus on supply security and capacity building to address pockets of high incidence.

Within Europe, the Middle East, and Africa, disparate healthcare models influence therapeutic uptake. High-income European nations maintain stringent surveillance for drug resistance and invest heavily in digital adherence tools, whereas some Middle Eastern countries prioritize state-funded treatment programs to ensure equitable access. Sub-Saharan Africa, facing the highest tuberculosis burden, contends with resource constraints that challenge the deployment of second-line regimens. Emerging regional manufacturing hubs aim to mitigate reliance on imports and enhance resilience against global supply chain disruptions.

The Asia-Pacific region, home to a substantial proportion of MDR tuberculosis cases, demonstrates pronounced heterogeneity in treatment accessibility. Southeast Asian countries have embraced community-based care models, decentralizing treatment through outpatient clinics and telemedicine platforms. In South Asia, public-private partnerships are pivotal in scaling up routine screening and standardized treatment initiation. The dynamic interplay of local production, innovative financing mechanisms, and targeted policy interventions continues to shape therapy availability, ultimately determining regional disease control trajectories.

Identifying Leading Company Strategies and Innovations Driving Progress in Multidrug-Resistant Tuberculosis Therapeutics and Healthcare Outcomes

Leading pharmaceutical companies have adopted multifaceted strategies to address the complexities of multidrug-resistant tuberculosis treatment. One prominent example is the development and global roll-out of bedaquiline, which demonstrated the potential of targeted drug discovery to transform clinical outcomes. Collaborative licensing agreements have enabled generic manufacturers to produce bedaquiline at lower cost, expanding access in regions where the disease burden is greatest. This approach showcases how strategic partnerships between originators and local producers can optimize affordability without compromising quality.

In addition to bedaquiline, novel combinations such as the pretomanid-based regimens have underscored the importance of integrated development pathways. By coordinating clinical trials across diverse geographies and patient demographics, developers have expedited the evaluation of safety and efficacy. Biotech emerging players are leveraging advanced screening technologies and structure-based drug design to identify new classes of antimicrobials capable of overcoming existing resistance mechanisms. These efforts are frequently supported by global health alliances that provide funding and facilitate regulatory harmonization.

Beyond molecular innovations, companies are investing in supply chain optimization and patient support initiatives. Cold-chain management solutions ensure the stability of temperature-sensitive compounds, while digital platforms guide adherence and monitor adverse events in real time. Manufacturers are also exploring outcome-based pricing agreements with payers, linking reimbursement to therapeutic performance metrics. Through these integrated strategies-encompassing research, production, and post-market support-industry leaders are charting a course toward more resilient and patient-centric approaches to combating multidrug-resistant tuberculosis.

Actionable Recommendations Empowering Industry Leaders to Enhance Access, Optimize Supply Chains, and Accelerate Innovation in MDR Tuberculosis Therapeutics

Stakeholders should prioritize local production partnerships to reduce reliance on international imports and buffer against tariff-induced cost fluctuations. Establishing joint ventures or licensing agreements with regional manufacturers can enhance supply chain resilience and foster technology transfer. In parallel, diversifying procurement channels by engaging multiple API suppliers will mitigate risks of single-source disruptions while supporting competitive pricing and continuous availability of essential compounds.

Investing in integrated digital health solutions will drive adherence and improve patient outcomes. Companies should collaborate with healthcare providers to deploy mobile applications that remind patients of dosing schedules, track side-effect profiles, and facilitate remote consultations. Implementing real-time data analytics across treatment cohorts allows for early identification of adherence challenges, enabling prompt intervention and reducing the likelihood of resistance amplification. This data-driven model also supports evidence generation for outcome-based contracting with payers and public health agencies.

To accelerate therapeutic innovation, industry leaders must engage in cross-sector consortia that align research objectives with public health priorities. Joint research initiatives can leverage shared preclinical models and harmonized regulatory pathways, expediting the translation of promising candidates from discovery to clinical evaluation. Furthermore, advocacy for streamlined regulatory review processes and prioritized market entry for high-need therapies will shorten time to patient access. By adopting these recommendations, organizations can enhance efficiency, sustain innovation, and ultimately improve care for patients confronting multidrug-resistant tuberculosis.

Detailing Rigorous Research Methodologies and Analytical Frameworks Underpinning the Comprehensive Study of Multidrug-Resistant Tuberculosis Therapies

This study integrates extensive secondary research to establish a foundational understanding of current therapeutic landscapes and resistance patterns. Peer-reviewed clinical publications, treatment guidelines from global health organizations, and clinical trial registries were systematically reviewed to capture the efficacy profiles of key antimicrobials. Regulatory filings and policy documents provided insights into import tariffs, pricing strategies, and market access considerations. Information from public health databases was synthesized to contextualize regional treatment protocols and patient demographics.

Complementing secondary insights, primary research encompassed in-depth interviews with experts in infectious disease, procurement specialists, and healthcare administrators. These discussions illuminated real-world challenges around drug availability, diagnostic workflows, and patient adherence strategies. Expert opinions guided the assessment of emerging pipelines, technology adoption curves, and potential bottlenecks in scaling new therapies. Cross-validation of qualitative data with documented clinical outcomes ensured robustness in the findings.

Analytical frameworks such as value-chain analysis facilitated evaluation of supply chain dynamics, while SWOT assessments identified internal strengths and external opportunities for market participants. A structured PESTEL review highlighted regulatory, economic, and technological factors influencing market dynamics. Data triangulation and consistency checks were applied throughout to maintain integrity and reduce bias. By combining rigorous methodological approaches and validated analytical models, this study delivers actionable insights rooted in the latest evidence and real-world perspectives.

Conclusive Perspectives Reinforcing the Imperative for Collaborative Efforts and Sustained Innovation to Combat the Global Threat of MDR Tuberculosis Therapies

Analysis confirms that tackling multidrug-resistant tuberculosis requires a cohesive strategy that aligns therapeutic innovation with health system strengthening. Breakthroughs in drug development and diagnostic technologies have created unprecedented opportunities to improve patient outcomes, yet these advances must be underpinned by resilient supply networks and supportive policy frameworks. Ensuring equitable access to novel therapies will depend on the ability of stakeholders to navigate regulatory complexities, optimize procurement mechanisms, and mobilize resources across diverse healthcare settings.

Collaboration among pharmaceutical developers, public health agencies, and non-governmental organizations will remain essential. Shared commitments to data transparency and open licensing can accelerate the adoption of effective regimens and mitigate the risk of emerging resistance. Simultaneously, investment in digital adherence tools and community-based care models must continue, bridging gaps between research breakthroughs and on-the-ground implementation. By fostering an ecosystem that incentivizes innovation and prioritizes patient-centered care, the global health community can make tangible progress against a disease that has long defied conventional treatment paradigms.

Ultimately, sustained impact hinges on continuous learning and adaptability. Ongoing monitoring of clinical outcomes, patient adherence trends, and resistance emergence will guide the refinement of therapeutic strategies. As stakeholders chart the path forward, a unified approach that integrates scientific discovery, operational resilience, and equitable access will determine success. This report provides a blueprint for such an approach, illuminating both the challenges that lie ahead and the opportunities to transform the management of multidrug-resistant tuberculosis through collaborative and sustained efforts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing adoption of all-oral bedaquiline and delamanid regimens to replace injectable therapies
  • 5.2. Regulatory pathways accelerating approval of novel compounds in multidrug-resistant TB treatment
  • 5.3. Integration of rapid molecular diagnostics and digital adherence technologies in personalized TB therapy
  • 5.4. Emergence of fixed-dose combination therapies shortening treatment duration for multidrug-resistant TB patients
  • 5.5. Price negotiation initiatives and donor-funded programs improving access to bedaquiline in low-income countries
  • 5.6. Clinical trial data on novel nitroimidazole pretomanid combinations informing updated WHO treatment guidelines
  • 5.7. Development of host-directed therapies alongside antibiotic regimens to reduce lung damage and improve outcomes
  • 5.8. Use of artificial intelligence models to predict TB drug resistance and optimize personalized MDR-TB regimens
  • 5.9. Scale-up of point-of-care therapeutic drug monitoring to personalize dosing in multidrug-resistant TB treatments
  • 5.10. Development of inhaled antimicrobial formulations for targeted pulmonary delivery in challenging MDR-TB cases to reduce systemic toxicity

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Multidrug-resistant Tuberculosis Therapeutics Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Bedaquiline
  • 8.3. Clofazimine
  • 8.4. Isoniazid
  • 8.5. Linezolid
  • 8.6. Rifampin

9. Multidrug-resistant Tuberculosis Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral

10. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Type

  • 10.1. Introduction
  • 10.2. Medication-Based Treatments
  • 10.3. Non-Medication Therapies

11. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Regimen Duration

  • 11.1. Introduction
  • 11.2. Long-Course Regimens
  • 11.3. Short-Course Regimens

12. Multidrug-resistant Tuberculosis Therapeutics Market, by End User

  • 12.1. Introduction
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacies
  • 13.3. Online Pharmacies
  • 13.4. Retail Pharmacies

14. Americas Multidrug-resistant Tuberculosis Therapeutics Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. GlaxoSmithKline plc
    • 17.3.2. Johnson & Johnson Services Inc.
    • 17.3.3. F. Hoffmann-La Roche Ltd
    • 17.3.4. Abcam Limited
    • 17.3.5. Eli Lilly and Company
    • 17.3.6. Lupin Limited
    • 17.3.7. Macleods Pharmaceuticals Ltd.
    • 17.3.8. Merck & Co., Inc.
    • 17.3.9. Mylan N.V.
    • 17.3.10. Novartis AG
    • 17.3.11. Otsuka Pharmaceutical Co., Ltd.
    • 17.3.12. Pfizer Inc.
    • 17.3.13. Sanofi SA
    • 17.3.14. WebMD LLC
    • 17.3.15. Viatris Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHAI
  • FIGURE 28. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHCONTACTS
  • FIGURE 30. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CLOFAZIMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CLOFAZIMINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LINEZOLID, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION-BASED TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION-BASED TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY NON-MEDICATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY NON-MEDICATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LONG-COURSE REGIMENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LONG-COURSE REGIMENS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SHORT-COURSE REGIMENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SHORT-COURSE REGIMENS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 54. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 55. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 56. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 57. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 59. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 67. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 68. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 69. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 70. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 71. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 74. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 81. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 82. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 83. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 84. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 85. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 88. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 89. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 90. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 93. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 94. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 95. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 96. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 97. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 100. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 101. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 103. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 104. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 105. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 106. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 107. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 109. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 112. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 113. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 115. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 116. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 117. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 118. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 119. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 121. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 123. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 124. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 125. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 127. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 155. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 157. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 159. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 162. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 163. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 165. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 167. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 169. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 171. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 174. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 175. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 179. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 180. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 181. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 183. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 186. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 187. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 191. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 193. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 195. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 198. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 199. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 201. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 203. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 205. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 207. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 210. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 211. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 227. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 234. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 246. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 251. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 253. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 255. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
  • TABLE 258. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
  • TABLE 259. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. DENMARK MULTIDRUG-RESISTA